scholarly journals Human Platelet Lysate Supports Efficient Expansion and Stability of Wharton’s Jelly Mesenchymal Stromal Cells via Active Uptake and Release of Soluble Regenerative Factors

2020 ◽  
Vol 21 (17) ◽  
pp. 6284
Author(s):  
Mariana Cañas-Arboleda ◽  
Karl Beltrán ◽  
Carlos Medina ◽  
Bernardo Camacho ◽  
Gustavo Salguero

Manufacturing of mesenchymal stromal cell (MSC)-based therapies for regenerative medicine requires the use of suitable supply of growth factors that enhance proliferation, cell stability and potency during cell expansion. Human blood derivatives such as human platelet lysate (hPL) have emerged as a feasible alternative for cell growth supplement. Nevertheless, composition and functional characterization of hPL in the context of cell manufacturing is still under investigation, particularly regarding the content and function of pro-survival and pro-regenerative factors. We performed comparative analyses of hPL, human serum (hS) and fetal bovine serum (FBS) stability and potency to support Wharton’s jelly (WJ) MSC production. We demonstrated that hPL displayed low inter-batch variation and unique secretome profile that was not present in hS and FBS. Importantly, hPL-derived factors including PDGF family, EGF, TGF-alpha, angiogenin and RANTES were actively taken up by WJ-MSC to support efficient expansion. Moreover, hPL but not hS or FBS induced secretion of osteoprotegerin, HGF, IL-6 and GRO-alpha by WJ-MSC during the expansion phase. Thus, hPL is a suitable source of factors supporting viability, stability and potency of WJ-MSC and therefore constitutes an essential raw material that in combination with WJ-MSC introduces a great opportunity for the generation of potent regenerative medicine products.

2015 ◽  
Vol 7 (3) ◽  
pp. 87-97 ◽  
Author(s):  
Andreas Ardhika Antoninus ◽  
Wahyu Widowati ◽  
Laura Wijaya ◽  
Dwi Agustina ◽  
Sugiarto Puradisastra ◽  
...  

2021 ◽  
Vol 16 (1) ◽  
pp. 71-85
Author(s):  
Vafa Meftahpour ◽  
Somaiyeh Malekghasemi ◽  
Amir Baghbanzadeh ◽  
Ali Aghebati-Maleki ◽  
Ramin Pourakbari ◽  
...  

Human platelet lysate has attracted much interest from many researchers as it is growth-factor rich for cell expansion, which is employed as a new therapeutic strategy. Not only are human platelet lysates used for cell therapy, but they are also used for the completion of basal media in mesenchymal stem cell cultures. Due to the presence of a large number of growth factors, platelet lysates have potential roles in wound healing, treatment of ocular graft-versus-host disease, osteoarthritis, Parkinson’s disease, tendon regeneration, infertility, androgenetic alopecia, nerve repair and regenerative tissue, such as bone regeneration. In this review, we summarize that platelet lysates could be valuable candidates for the treatment of a variety of diseases in regenerative medicine.


2019 ◽  
Vol 58 (6) ◽  
pp. 102674 ◽  
Author(s):  
Thierry Burnouf ◽  
Lassina Barro ◽  
Ouada Nebie ◽  
Yu-Wen Wu ◽  
Hadi Goubran ◽  
...  

2021 ◽  
Vol 22 (10) ◽  
pp. 5178
Author(s):  
Michaela Oeller ◽  
Sandra Laner-Plamberger ◽  
Linda Krisch ◽  
Eva Rohde ◽  
Dirk Strunk ◽  
...  

Numerous cell-based therapeutics are currently being tested in clinical trials. Human platelet lysate (HPL) is a valuable alternative to fetal bovine serum as a cell culture medium supplement for a variety of different cell types. HPL as a raw material permits animal serum-free cell propagation with highly efficient stimulation of cell proliferation, enabling humanized manufacturing of cell therapeutics within a reasonable timeframe. Providers of HPL have to consider dedicated quality issues regarding identity, purity, potency, traceability and safety. Release criteria have to be defined, characterizing the suitability of HPL batches for the support of a specific cell culture. Fresh or expired platelet concentrates from healthy blood donors are the starting material for HPL preparation, according to regulatory requirements. Pooling of individual platelet lysate units into one HPL batch can balance donor variation with regard to essential platelet-derived growth factors and cytokines. The increasingly applied pathogen reduction technologies will further increase HPL safety. In this review article, aspects and regulatory requirements of whole blood donation and details of human platelet lysate manufacturing are presented. International guidelines for raw materials are discussed, and defined quality controls, as well as release criteria for safe and GMP-compliant HPL production, are summarized.


2019 ◽  
Vol 19 (8) ◽  
pp. 1177-1191 ◽  
Author(s):  
Rosy Vennila ◽  
Raja Sundari M. Sundaram ◽  
Sakthivel Selvaraj ◽  
Prasanna Srinivasan ◽  
Surajit Pathak ◽  
...  

Background: Mesenchymal stem cells (MSCs) are highly preferred in clinical therapy for repair and regeneration of diseased tissues for their multipotent properties. Conventionally, MSCs have been cultured in media supplemented with animal derived serum, however, it is ideal to expand MSCs in media containing supplements of human origin for clinical therapy. Currently, a number of human derived products are being studied as an alternative to animal sources. Amongst these, platelet lysate (PL) has gained interest in the culture of MSCs without affecting their phenotypic property. Objective: In this study, we used various concentration of PL (2.5, 5, 7.5 & 10%) in the growth medium of MSCs to identify the least concentration of PL that could be an effective alternative to animal products. Methods: MSCs were isolated from Wharton’s Jelly by using explant method and expanded in various concentration of PL supplemented medium against the standard FBS containing medium. WJ-MSCs were characterised as per the minimal criteria proposed by International Society for Cell therapy (ISCT), Proliferation study by BrdU assay, gene expression study by qRT-PCR, sterility test for bacteria, Mycoplasma by PCR and endotoxin detection by LAL assay. Results: Whartons jelly derived MSCs (WJ-MSCs) cultured using standard medium supplemented with various concentration of PL exhibited enhanced proliferation and differentiation potential, unaltered immunophenotypic property and genetic stability when compared with the commercial medium containing 10% FBS. Conclusion: The least concentration of PL for an ideal expansion of MSCs was found to be 2.5% and was comparable to FBS.


2021 ◽  
Vol 206 ◽  
pp. 108493
Author(s):  
Gina L. Griffith ◽  
Andrew W. Holt ◽  
Elof Eriksson ◽  
Anthony J. Johnson ◽  
Jennifer S. McDaniel

Sign in / Sign up

Export Citation Format

Share Document